title: FKBP51 protects 661w cell culture from staurosporine-induced apoptosis.
abstract: OBJECTIVE
  Neurodegenerative diseases and neurotraumas typically result in apoptosis of specific neurons leading to the pathology observed during the disease state. Existing treatments target the symptoms instead of preventing the death of these neurons. Although neuroprotective drugs should be useful as a treatment to prevent further loss of neurons, efficacious molecules are lacking. FK506 (tacrolimus), a widely used immunosuppressant drug, has significant neuroprotective and neuroregenerative properties throughout the central nervous system, including the eye. FK506 achieves these properties through interaction with FK506 binding proteins (FKBP), including FK506 binding protein 51 (FKBP51). In this study, we examine the effects of FKBP51 as a neuroprotective agent on a neuronal cell line.
  
  
  METHODS
  We cultured 661w cell cultures with or without FK506, or stably transfected them with an FKBP51 expression vector. These cells were then exposed to the apoptosis-inducing agent staurosporine. Cell viability was determined using a calcein AM/propidium iodide assay. Protein levels and activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) were determined by western immunoblot analysis.
  
  
  RESULTS
  FKBP51 overexpression significantly protected 661w cell cultures from staurosporine-induced apoptosis. FKBP51 overexpression also significantly increased NF-κB p65 protein levels and activated NF-κB p65. FK506 treatment significantly protected 661w neuronal cultures from staurosporine-induced apoptosis. FK506 increased FKBP51, NF-κB p65, and levels of activated NF-κB p65 protein.
  
  
  CONCLUSIONS
  These results suggest that FKBP51 protects 661w cell cultures from apoptosis induced by staurosporine. Additionally, FK506 protected 661w cell cultures from apoptosis and displayed a mechanism similar to that of FKBP51 overexpression. Both FK506 and FKBP51 appear to act through activation of NF-κB p65 protein, suggesting a common pathway for neuroprotection. These findings implicate FKBP51 as a protein important to neuronal cell culture survival. FKBP51 may be a potential therapeutic drug target for preventing the neurodegeneration and neurotrauma that occur during neurodegenerative diseases.
authors: Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
authors: Donald Raymond
authors: DR
authors: Daudt
authors: Thomas
authors: T
authors: Yorio
references: Br J Dermatol. 2005 Oct;153(4):701-5
references: 16181449
references: Eur J Neurosci. 2001 May;13(9):1683-93
references: 11359520
references: Can J Physiol Pharmacol. 2008 Jun;86(6):380-93
references: 18516102
references: J Clin Invest. 1996 Jun 1;97(11):2433-9
references: 8647935
references: Antioxid Redox Signal. 2007 Aug;9(8):1059-96
references: 17571960
references: Cancer Res. 2005 Apr 15;65(8):3281-9
references: 15833861
references: Anal Biochem. 1981 Apr;112(2):195-203
references: 6266278
references: Neuroscience. 1999 Jan;88(1):257-67
references: 10051205
references: J Urol. 2005 May;173(5):1772-7
references: 15821585
references: Neurochem Res. 2008 Dec;33(12):2444-71
references: 18629638
references: Curr Drug Targets CNS Neurol Disord. 2003 Jun;2(3):153-62
references: 12769796
references: Nucleic Acids Res. 2009 Jul;37(12):4135-48
references: 19433513
references: Exp Dermatol. 2007 May;16(5):385-93
references: 17437481
references: Science. 1996 Nov 1;274(5288):782-4
references: 8864118
references: Nature. 1970 Aug 15;227(5259):680-5
references: 5432063
references: Urology. 2005 May;65(5):1003-7
references: 15882753
references: Exp Hematol. 2003 Jul;31(7):622-30
references: 12842707
references: Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12242-7
references: 16103353
references: Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9328-32
references: 7568127
references: J Neurosci. 1998 Oct 15;18(20):8186-97
references: 9763465
references: Invest Ophthalmol Vis Sci. 2004 Mar;45(3):764-8
references: 14985288
references: J Immunol. 2009 Jun 1;182(11):7201-11
references: 19454717
references: Cell Death Differ. 2010 Jan;17(1):145-57
references: 19696786
references: Neurosci Lett. 2002 Mar 15;321(1-2):53-6
references: 11872255
references: Br J Cancer. 2003 Jul 21;89(2):391-7
references: 12865934
references: EMBO Rep. 2005 Apr;6(4):321-6
references: 15809659
references: J Neurosci. 2010 Jan 13;30(2):591-9
references: 20071522
references: Blood. 2002 Oct 15;100(8):2932-40
references: 12351405
references: J Neurochem. 2010 May;113(4):904-18
references: 20202085
references: Braz J Med Biol Res. 2003 Apr;36(4):495-502
references: 12700828
references: Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3191-5
references: 7512727
references: Mol Cell Biol. 2010 Mar;30(5):1243-53
references: 20048054
references: Cell Death Differ. 2010 Nov;17(11):1785-94
references: 20489733
references: Invest Ophthalmol Vis Sci. 2000 Apr;41(5):1111-5
references: 10752948
references: J Neurosci Res. 1999 Dec 1;58(5):607-11
references: 10561688
references: J Neurochem. 2008 Nov;107(4):1158-67
references: 18823372
references: Eur J Haematol. 2004 Apr;72(4):239-44
references: 15089760
references: Apoptosis. 2010 Jun;15(6):715-27
references: 20333467
references: Neurosci Lett. 2002 Sep 20;330(2):147-50
references: 12231433
references: Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4
references: 388439
references: Drug Discov Today. 2004 Mar 1;9(5):210-8
references: 14980539
references: J Neurochem. 2000 Feb;74(2):443-56
references: 10646495
references: Clin Pharmacol Ther. 2010 Oct;88(4):427-30
references: 20856233
references: J Cell Mol Med. 2004 Jan-Mar;8(1):45-58
references: 15090260
references: Eur J Pharmacol. 2006 Sep 1;545(1):22-8
references: 16854410
references: Methods Mol Biol. 2007;399:99-124
references: 18309928